Skip to main content

Dr. John P. Carlson, MD

Ophthalmology (Ophthalmology Physician)

9041 Magnolia Ave, Suite 207
Riverside, CA 92503

Who else practices at this address →

Riverside County includes primary care (1% of residents) and mental health (5% of residents) shortage areas. About shortage areas

Call (951) 788-0222

  • Medicare participating

At a glance

Years since graduation
31
In the NPI registry since
2005
Medicare patients seen, 2024
797

Licensed in California since 1997, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1995Medical school: Creighton University School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Ophthalmology Physician primary
    CA license A62397 (first issued 1997; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Ophthalmology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
797
Services billed
24,966
Patients’ average age
78
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, faricimab-svoa, 0.1 mg11,28036
Imaging of retina1,437518
Injection of drug into eye981210
Injection, ranibizumab, 0.1 mg89252
Established patient office or other outpatient visit, 30-39 minutes698469
Injection, pegcetacoplan, intravitreal, 1 mg60023
Injection, aflibercept, 1 mg53466
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg46839
Photography of the retina317233
Extended exam of the back part of the eye with optic nerve drawing236191

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 22 payments worth $634 in total to this clinician.

By type
Food and Beverage$634

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $1,000,671 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
    Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914
  • A phase iii study to investigate RO7200220 in patients with uveitic macular edema
    Genentech, Inc.
  • A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
    Kyowa Kirin, Inc.
  • BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
    Bayer HealthCare Pharmaceuticals Inc.
  • A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
    Astellas Pharma Global Development
  • A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
    Regeneron Pharmaceuticals, Inc.
  • A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
    Janssen Research & Development, LLC
  • A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Ophthalmology clinicians in Riverside

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 27, 2011), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1215913199. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.